MedPage Today on MSN
FDA Gives Broad Approval to Gene Therapy for Rare Neurologic Disease
The FDA approved the intrathecal gene therapy onasemnogene abeparvovec (Itvisma) to treat spinal muscular atrophy (SMA) in ...
Novartis is pricing Itvisma at a wholesale acquisition cost of $2.59 million, a company spokesperson told Fierce Pharma. At ...
The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...
Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...
There is an ongoing debate about the merits of cardio over lifting that sometimes feels more like justifying one’s behavior ...
Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.
The only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA).
From my video the most muscular players in the mlb today. Who do you think it is? #mlb #baseball #fypシ Marjorie Taylor Greene ...
The Great Khali might be a WWE Hall of Famer, but he's not remembered for his in-ring work. In fact, it's usually the ...
The paparazzi spotted Sebastian Stan walking around town in a casual workout look. The Marvel actor showed off his muscular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback